At the Molecular Medicine Tri-Conference, held March 6-11, Dr. Grace Zhao, co-founder and research director of AccuraGen, first published Encore Authentic ctDNA high-throughput sequencing technology.

The principle of FireflyTM and its performance comparison with mainstream international technology prove that the genetic liquid biopsy product developed based on FireflyTM technology may be the best performing ctDNA high-throughput sequencing product in the world. This means that the international company initiated by Chinese overseas scholars is at the forefront of the world in the field of tumor liquid biopsy. A few days ago, GenomeWeb, an internationally renowned genomics professional website, reported on this. The San Francisco Molecular Medicine Tripartite Conference has a history of 23 years, focusing on molecular medicine, covering new drug research and development, genomics, in vitro diagnostics, bioinformatics, business strategy, platform development and many other fields. It is a first-class candidate for diagnostic methods and new drug research and development. International event.

Two major technical barriers to accurate sequencing of ctDNA

Liquid biopsy is the hottest star technology in the field of precision medicine for cancer. Circulating tumor DNA (ctDNA) high-throughput sequencing technology is one of the most promising liquid biopsies. It only needs to collect venous blood like liver and kidney function, and can accurately measure the tumor gene information of the whole body. Based on the tumor gene information, it can guide the selection of anti-tumor drugs, evaluation of efficacy, prognosis judgment, and even early detection and early diagnosis. . However, there are two major technical hurdles in the accurate sequencing of ctDNA: first, the ctDNA content in plasma is extremely low, and few detection reactions are impossible. Secondly, the background noise of the second generation sequencing is very high. The tumor signal is completely submerged in the background noise by the conventional database sequencing method. The top players in this field in the world are working to overcome these two problems.

A photo of the American R&D team of AccuraGen (from left to right: Dr. Paul Tang, co-founder, director of genomics; Dr. Grace Zhao Qizhi, co-founder and research director; Sun Zhaohui, master co-founder, CIO; Lin Shengyu Ph.D., co-founder, president and CTO; Dr. Weng Li, Vice President of Product Development; Dr. Malek Faham, CSO)

ctDNA detection technology with up to 98% verification rate of tissue sequencing

Dr. Zhao Qizhi presided over the meeting on March 11th in the Circulating Tumor DNA Session and reported on the principles and progress of FireflyTM technology. Anco's single-chain cyclized DNA rolling circle replication tandem repeat confirmation method replaces the international mainstream double-stranded DNA molecular barcode amplification alignment confirmation method, which greatly improves the problem of DNA amplification of a small amount of circulating tumors. Detection sensitivity and specificity. Based on this technology, the feasibility-enhancing TM products covering 61 gene sequencing have been verified, and six clinical collaborative research projects for different cancer types are being promoted in China. Clinical studies have demonstrated a coincidence rate of 98% of ctDNA with tissue sequencing and up to 87% of site coincidence rates in advanced lung cancer cases. Through the study of pancreatic cancer in the past two years, the correlation between ctDNA mutation spectrum and prognosis and chemotherapy benefit rate was found. In the study of direct colon cancer drug guidance, a clear correlation between ctDNA and efficacy and recurrence was found. These research results have been submitted to the annual meeting of the American Society of Clinical Oncology (ASCO) in June this year, which also laid a solid foundation for the next product development.

Liquid biopsy can reflect the whole tumor

A few years ago, Apple founder Jobs spent $100,000 on tumor gene sequencing, and he could only take biopsy specimens of tumor tissue, which is very limited in practical applications. Liquid biopsy, which only requires blood collection, is extremely convenient to use. Not only that, tissue biopsy like a blind person or cut a cake, only a part of the tumor is detected, and ctDNA in the circulating blood can reflect the overall appearance of the tumor, which provides an unprecedented view of comprehensive understanding of tumor characteristics and precise administration. At present, Ankeji Company, which was founded in Palo Alto, California, more than two years ago, has moved to Menlo Park to form a world-class R&D team. At the same time, it established the first medical laboratory and commercial promotion organization in Shanghai, China. It is reported that the company will have further development layout in the near future and it is worth looking forward to.

Frozen Squid Fillet

Zhoushan Fudan Tourism CO., LTD , https://www.fudanfood.com